SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 86 filers reported holding SPERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $183 | -16.4% | 151 | 0.0% | 0.00% | – |
| Q2 2023 | $219 | 0.0% | 151 | 0.0% | 0.00% | – |
| Q1 2023 | $219 | -16.1% | 151 | 0.0% | 0.00% | – |
| Q4 2022 | $261 | – | 151 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 151 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 151 | -86.9% | 0.00% | – |
| Q1 2022 | $10,000 | -44.4% | 1,151 | 0.0% | 0.00% | – |
| Q4 2021 | $18,000 | 0.0% | 1,151 | +15.1% | 0.00% | – |
| Q3 2021 | $18,000 | -57.1% | 1,000 | -66.7% | 0.00% | – |
| Q2 2021 | $42,000 | -4.5% | 3,000 | 0.0% | 0.00% | – |
| Q1 2021 | $44,000 | -24.1% | 3,000 | 0.0% | 0.00% | – |
| Q4 2020 | $58,000 | +75.8% | 3,000 | 0.0% | 0.00% | – |
| Q3 2020 | $33,000 | +135.7% | 3,000 | +200.0% | 0.00% | – |
| Q2 2020 | $14,000 | +250.0% | 1,000 | +100.0% | 0.00% | – |
| Q1 2020 | $4,000 | -20.0% | 500 | 0.0% | 0.00% | – |
| Q4 2019 | $5,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |